Want to see HK:6998 full AI Analyst Report?
6998 Stock Chart & Stats
HK$3.06
HK$0.04(2.16%)
At close: 4:00 PM EST
HK$3.06
HK$0.04(2.16%)
Day’s Range― - ―
52-Week RangeHK$1.42 - HK$5.60
Previous CloseN/A
Volume193.50K
Average Volume (3M)909.38K
Market Cap
HK$3.01B
Enterprise ValueHK$4.49K
Total Cash (Recent Filing)HK$1.06B
Total Debt (Recent Filing)HK$1.49B
Price to Earnings (P/E)5.4
Beta0.41
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,014,041,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.17
Price to Sales (P/S)1.67
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Profitability InflectionThe shift from losses to meaningful operating and net profitability shows that the biologics platform can potentially convert development and commercialization activity into earnings, strengthening the company’s fundamental base if this performance is sustained.
Positive Cash GenerationOperating and free cash flow turning positive provides internally generated funding for research, manufacturing and commercialization. Free cash flow near net income also supports the quality of reported 2025 profitability and reduces reliance on external capital.
Meaningful Equity BaseA substantial equity base and moderate leverage provide some financial flexibility for a capital-intensive biotechnology business. This can support ongoing biologics development and production while limiting balance-sheet pressure relative to a highly debt-funded model.
Bears Say
Earnings Durability RiskThe sharp 2025 improvement follows several years of losses and irregular or absent reported revenue. That history makes it difficult to establish a repeatable earnings engine, increasing the risk that recent profitability reflects a transitional rather than durable business state.
Sharp Debt IncreaseAlthough leverage remains moderate, the rapid increase in debt adds fixed financial obligations after a period of weak profitability. If biologics development or commercialization underperforms, higher debt could reduce flexibility and amplify pressure on future cash flows.
Unproven Cash-Flow StabilityThe 2025 cash-generation improvement is encouraging but has not been demonstrated across operating cycles. Prior negative cash flow and large base effects mean the company may still require substantial funding if product timing, demand or development spending becomes less favorable.
Genor Biopharma Holdings Limited News
6998 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was HK$1.42 and its highest was HK$5.60 in the past 12 months.
What is Genor Biopharma Holdings Limited’s market cap?
Genor Biopharma Holdings Limited’s market cap is HK$3.01B.
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
Genor Biopharma Holdings Limited’s upcoming earnings report date is Mar 31, 2027 which is in 213 days.
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Currently, no data Available
Is Genor Biopharma Holdings Limited overvalued?
According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued.
Does Genor Biopharma Holdings Limited pay dividends?
Genor Biopharma Holdings Limited does not currently pay dividends.
What is Genor Biopharma Holdings Limited’s EPS estimate?
Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genor Biopharma Holdings Limited have?
Genor Biopharma Holdings Limited has 2,014,041,700 shares outstanding.
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
Currently, no hedge funds are holding shares in HK:6998
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Originally named JHBP (CY) Holdings Limited, the company adopted its current moniker, Genor Biopharma Holdings Limited, in June 2021. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
Technical Analysis
Antengene Corporation Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―